Bioprocess optimization for purification of chimeric VLP displaying BVDV E2 antigens produced in yeast Hansenula polymorpha.
J Biotechnol
; 306: 203-212, 2019 Dec 20.
Article
em En
| MEDLINE
| ID: mdl-31634510
ABSTRACT
Chimeric virus-like particles (VLP) are known as promising tools in the development of safe and effective subunit vaccines. Recently, a technology platform to produce VLP based on the small surface protein (dS) of the duck hepatitis B virus was established. In this study, chimeric VLP were investigated displaying the 195 N-terminal amino acids derived from the glycoprotein E2 of the bovine viral diarrhea virus (BVDV) on their surface. Isolation of the VLP from methylotrophic yeast Hansenula polymorpha was allowed upon co-expression of wild-type dS and a fusion protein composed of the BVDV-derived antigen N-terminally fused to the dS. It was shown the VLP could be purified by a process adapted from the production of a recombinant hepatitis B VLP vaccine. However, the process essentially depended on costly ultracentrifugation which is critical for low cost production. In novel process variants, this step was avoided after modification of the initial batch capture step, the introduction of a precipitation step and adjusting the ion exchange chromatography. The product yield could be improved by almost factor 8 to 93 ± 12 mg VLP protein per 100 g dry cell weight while keeping similar product purity and antigenicity. This allows scalable and cost efficient VLP production.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Pichia
/
Vacinas Virais
/
Proteínas do Envelope Viral
/
Vírus da Diarreia Viral Bovina
/
Vacinas de Partículas Semelhantes a Vírus
Idioma:
En
Ano de publicação:
2019
Tipo de documento:
Article